What will OSL's share price do if CE Mark approval is granted in one or both of its applications (pancreatic and liver)?
The target approval date is end Q3 2015. Recent ISO certification might suggest CE Mark approval can be gained sooner although it is probably safer being conservative.
CE Mark approval by Australian companies is infrequent and a number of applications have been inglorious failures. My sense is that OSL is being very diligent in putting its application together and has a credible chance of approval being granted.
In my opinion the share price will rise strongly if CE Mark approval is granted, especially if so for both pancreatic and liver cancer.
Beyond that OSL needs to demonstrate a well thought out sales plan, an ability to execute upon that plan, and a quick transition to a company that generates revenues for further share price rerating. This is a big and do-able opportunity for management and particularly the new CEO. I hope they can deliver. OSL needs to start communicating on these matters - a notable absence in its just released investor presentation - to show that it understands and is on top of these issues.
OSL Price at posting:
11.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)